✦ LIBER ✦

Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide

✍ Scribed by Graeme Sangster; W. Nigel Patton; Richard I. Harris; Robert J. Grieve; Michael J. Leyland

Publisher: Springer
Year: 1989
Tongue: English
Weight: 336 KB
Volume: 23
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00451654

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ifosfamide, etoposide, cytarabine, and m

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

✍ Aspasia Stamatoullas; Christophe Fruchart; Dominique Bastit; Dominique Boulet; M 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

Ifosfamide and mitoxantrone (I-M) in rel

Ifosfamide and mitoxantrone (I-M) in relapsed and refractory high grade non-Hodgkin's lymphoma and Hodgkin's disease

✍ G. J. Dovey; Dr. J. A. Child; A. V. Simmons; D. L. Barnard; L. Parapia; M. Morga 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

Fifty-five patients, initially diagnosed as having advanced high grade non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) refractory to first-line treatment or in relapse, were treated with ifosfamide 6 g/m', infused over 48 h, followed by mitoxantrone 12 mg/m2. The regimen repeated at three-wee

Etoposide, ifosfamide and methotrexate c

Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-hodgkin's lymphoma after failure of the LNH 84 regimen

✍ R. Herbrecht; S. Ortiz; J. C. Damonte; K. L. Liu; F. Maloisel; P. Dufour; J. P. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB

We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 8

Salvage therapy for non-Hodgkin's lympho

Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin

✍ Nissim Haim; Edward Rosenblatt; Mira Wollner; Menachem Ben-Shahar; Ron Epelbaum; 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 236 KB

Cladribine in the treatment of advanced

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

✍ Anil Tulpule; Gary Schiller; Laura A. Harvey-Buchanan; Myung Lee; Byron M. Espin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog with cytotoxic activity against both resting and proliferating cells. Clinical studies with cladribine have reported antitumor activity against various hematologic malignancies.

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated